Impact of 10 Mg Rosuvastatin Daily or Alternate-Day on Lipid Profile and Inflammatory Markers

Jian-Jun Li,Ping Yang,Jun Liu,Yan-Jun Jia,Zi-Cheng Li,Yuan-Lin Guo,Na-Qiong Wu,Yi-Da Tang,Li-Xin Jiang
DOI: https://doi.org/10.1016/j.cca.2011.09.006
IF: 6.314
2012-01-01
Clinica Chimica Acta
Abstract:Background: Statins are commonly administrated daily, while rosuvastatin can be given every other day due to its longer half-lives. We evaluated the potential efficacy of alternate-day dosing of 10 mg rosuvastatin compared with daily dosing of 10 mg rosuvastatin with regarding to lipid and inflammatory markers in patients with dyslipidemia.Methods: Thirty-seven patients were randomly divided into the 2 groups: alternate-day group (rosuvastatin 10 mg every other day. n = 19) and once-daily group (rosuvastatin 10 mg every day, n = 18) for 6 weeks. The primary endpoints of the study were changes of the serum concentrations of low-density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP) and interleukin-6 (IL-6) following 6-week rosuvastatin therapy.Results: Baseline characteristics of the 2 groups were well balanced. LDL-C decreased by 37.5% after the once-daily dosing period and by 36.9% after alternate-day dosing period (p > 0.05). Both dosing regimens provided similar improvement in high-density lipoprotein cholesterol and triglyceride. And also, both dosing regimens significantly decreased serum concentrations of CRP, which had an 18.3% reduction in once-daily dosing and a 16.7% reduction in alternate-day dosing of rosuvastatin ( p > 0.05). Moreover, the pattern of plasma IL-6 concentrations was also similar between the two groups (p > 0.05).Conclusions: Alternate-day dosing of rosuvastatin could be effective comparable with once-daily dosing of rosuvastatin in Chinese patients in improving not only lipid profile but also inflammatory markers, which may provide some cost savings and increase the compliance of patients. (C) 2011 Elsevier B.V. All rights reserved.
What problem does this paper attempt to address?